Back to News >

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today (January 7, 2020) announced the launch of its VivopureX™ recombinant mouse antibodies for in vivo research in mouse models.

The collection consists of popular antibody clones, many originally obtained from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions to improve research results.

The antibodies are all available in discounted bulk sizes ranging from 1 mg to 100 mg.

VivopureX™ antibodies are species-matched chimeric antibodies, consisting of a clone’s original antigen-binding variable domain with a mouse constant domain, which means they do not induce neutralizing antibodies in mouse models.

As a result, the engineered recombinant antibodies offer many advantages compared to the original monoclonal antibodies, including increased long-term efficacy, stronger potency and a more consistent response across cohorts.

In addition, VivopureX™ antibodies feature engineered effector functions, with Fc receptor binding tailored to best suit popular applications such as depletion, agonism or blocking.

All antibodies are produced recombinantly for ensured batch-to-batch reproducibility, and offer high purity and low endotoxin levels ideal for in vivo applications.

The antibodies are targeted against key immune system proteins, including clinically relevant checkpoint proteins such as PD-1, CTLA-4 and OX40.

Absolute Antibody data has shown that the recombinant mouse PD-1 antibody, based on the widely used clone RMP1-14, reduces tumor size in a mouse model more effectively than the original rat version.

Dr. Michael Fiebig, Director of Products and Innovations at Absolute Antibody said:

“The VivopureX™ antibody collection includes a selection of our most exciting mouse-anti-mouse antibodies, now available at discounted bulk prices ideal for in vivo researchers,”

“Most antibodies currently used in vivo are immunogenic, leading to adverse immunological reactions and gradual loss of activity.

By applying the same protein engineering approaches used in therapeutic development to research reagents, we can improve in vivo research results and further our understanding into the mechanisms underlying immunotherapy.”

For more information, and a full list of available antibody targets, please visit our website here.